Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05566210
Other study ID # S266
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date August 30, 2025

Study information

Verified date September 2022
Source Huazhong University of Science and Technology
Contact Cuihong Zheng, Professor
Phone 86-27-83663275
Email chzheng@tjh.tjmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The randomized, placebo-controlled multicenter trial is conducted in three centers in China. After screening and obtaining the signed informed consent, the participants are randomly divided into two groups: acupuncture group and sham acupuncture group.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date August 30, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: 1. Infertile women older than 18 years and younger than 40 years to undergo fresh IVF or self-pregnant; 2. AMH<1.1 ng/ml; 3. total AFC< 7; 4. 10 U/L<FSH< 25IU/L,?FSH/LH>2.6; 5. had a history of low ovarian response once, and the number of eggs obtained in IVF was less than 3 (at least two of the 2)3)4)5 )items are required); 6. Willing to accept randomized grouping, treatment arrangement and follow-up, and signing informed consent. Exclusion Criteria: Patients who met any of the following conditions were not included: 1. Severe abnormality of uterine cavity caused by adenomyosis, uterine fibroids, endometrial polyps, tuberculosis of the reproductive system, endometritis, abnormal endometrial thickness (HCG day of the previous IVF cycle is less than 7mm or greater than 14mm); 2. Patients with other endocrine diseases, such as thyroid disease, hyperprolactinemia, insulin resistance, diabetes, adrenal disease, etc., and poor control of hormone levels in the last 3 months; 3. Clearly diagnosed autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, etc.; 4. Untreated hydrosalpinx; 5. Body mass index (BMI) higher than 28 kg/m; 6. The male or female chromosome abnormality; 7. People with previous history of acupuncture sickness; 8. Those who have previously participated in the study or are currently receiving acupuncture treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
acupuncture
acupuncture
Sham acupuncture
Sham acupuncture

Locations

Country Name City State
China Tongji Hospital,Tongji medical college,HUST Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Huazhong University of Science and Technology

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary AFC Antral follicle count on the 3rd day of menstruation
Secondary Blood levels of FSH, LH, E2 and AMH on the 3rd day of menstruation on the 3rd day of menstruation
Secondary ß-HCG positive pregnancy rate Two weeks after ET or when menstruation expired for natural pregnancy
Secondary Clinical pregnancy rate 4 weeks after ET or natural pregnancy: B ultrasonography was used to observe whether there were pregnant sac and cardiac tube pulsation in uterine cavity
Secondary Live birth rate Gestation greater than 24 weeks and birth as a live fetus
See also
  Status Clinical Trial Phase
Recruiting NCT06332742 - Real-world Evaluation of Qingxin Zishen Decoction on Ovarian Reserve Function Clinical Efficacy in Patients With Decreased
Terminated NCT00419913 - A Trial of Dehydroepiandrosterone (DHEA) Treatment for in Vitro Fertilization (IVF) Phase 2/Phase 3